Health
UniQure’s Huntington’s Disease Treatment Approved for Resubmission
The FDA has reversed its previous opposition to UniQure's experimental treatment for Huntington’s disease, allowing the company to resubmit its application. This could be a significant step in treating this debilitating condition.
Coverage timeline — 1 article
STAT News
The FDA has reversed its opposition to a closely watched experimental treatment for Huntington’s disease, clearing a path for its maker.
2026-06-17 11:43 UTC